Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alectinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK known ✓ | Q9UM73 | 20/20 | 1.00 |
| ▸ | EML4 known ✓ | Q9HC35 | 2/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | ACOX3 | O15254 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ROS1 | P08922 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | EPHA1 | P21709 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alectinib SCHEMBL29352499 | 1.00 | ALK (1.00) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL18631602 | 1.00 | ALK (1.00) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL31372326 | 0.99 | ALK (0.98) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL14991271 | 0.99 | ALK (0.98) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL29360318 | 0.99 | ALK (0.98) | ALKKDREML4GAKACOX3 | |
| SCHEMBL896761 | 0.95 | ALK (1.00) | ALKKDREML4GAKACOX3 | |
| SCHEMBL898391 | 0.94 | ALK (0.89) | ALKKDREML4GAKACOX3 | |
| SCHEMBL29962525 | 0.94 | ALK (0.89) | ALKKDREML4GAKACOX3 | |
| SCHEMBL898293 | 0.93 | ALK (0.87) | ALKKDREML4GAKACOX3 | |
| SCHEMBL29962638 | 0.93 | ALK (0.87) | ALKKDREML4GAKACOX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 657 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281408-A1 | AMORPHOUS SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Shenzhen Pharmacin Co., Ltd. (CN) | 2025-09-11 | — | — | US | claimed |
| US-20250243179-A1 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-31 | — | — | US | claimed |
| US-20250241964-A1 | SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2025-07-31 | — | — | US | claimed |
| US-20250134900-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN-LA ROCHE INC. (US) | 2025-05-01 | — | — | US | claimed |
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | claimed |
| EP-4499047-A1 | AMORPHOUS SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Shenzhen Pharmacin Co., Ltd. (CN) | 2025-02-05 | — | — | EP | claimed |
| US-20240299403-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN-LA ROCHE INC. (US) | 2024-09-12 | — | — | US | claimed |
| WO-2024079755-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | claimed |
| WO-2023179774-A1 | AMORPHOUS SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-09-28 | — | — | WO | claimed |
| US-9440922-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | claimed |
| US-9365514-B2 | Composition comprising tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-06-14 | — | — | US | claimed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | claimed |
| WO-2015193309-A1 | NEW PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-23 | — | — | WO | claimed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | claimed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2606886-A1 | COMPOSITION CONTAINING TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2013-06-26 | — | — | EP | claimed |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-06 | — | — | US | claimed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | claimed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281408-A1 | AMORPHOUS SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LPXN, AR, ALB | ALK 8/4885EML4 413/4885RET 322/4885 |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885EML4 2904/4885RET 96/4885 |
| US-20250243179-A1 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | CYP2D6, CALU, CYP3A4 | ALK 175/4885EML4 83/4885RET 3413/4885 |
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885EML4 2904/4885RET 96/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885EML4 264/4885RET 30/4885 |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885EML4 2904/4885RET 96/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885EML4 264/4885RET 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.